You are here

Figure 1

Figure 1
Figure 1

Effect of daratumumab on the pathogenic autoantibodies in the two SjD patients. (A) Follow-up of anti- GPIHBP1 antibodies (Ab) titre and triglycerides (TG) levels. (B) Follow-up of RF titre. Red dotted line represents the TG normality threshold. Blue dotted line represents anti-GPIHBP1 threshold. Green arrows represent daratumumab infusion. Purple arrows represent RTX infusion. RF, rheumatoid factor; RTX, rituximab; SjD, Sjögren disease.

Vol 10 Issue 2 Table of Contents
Email
Alerts
Citation Tools
Cite This
Download Powerpoint
Save to my folders

Share this article

Click the icon of the social media platform on which you would like to share this article.

Twitter logo Facebook logo LinkedIn logo

Email this article to a friend

We will not keep your email address; we ask for it so your friend knows the email isn't spam.
Enter multiple addresses on separate lines or separate them with commas.
Figure 1
(Your Name) has forwarded a page to you from RMD Open
(Your Name) thought you would like to see this page from the RMD Open web site.
CAPTCHA
This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.

Request permissions

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.

Respond to this article
Add to Selected Citations
View Selected Citations (0)

Related Articles

Cited By...

Similar Articles